Complete remission of an advanced hormone receptor positive Her2-negative breast cancer treated by first line palbociclib-letrozole and local treatment
The palbociclib-letrozole combination has revolutionized the treatment of Hormone-receptor-positive Her2-negative advanced breast cancers. The aim of the inclusion of targeted agents in endocrine based therapy is to prolong hormonsensitivity and to delay the initiation of subsequent chemotherapy, especially for patients with low disease burden. However, the interest of locoregional treatment after response to initial therapy in advanced disease still investigational especially in the era of biotherapy. In the present case report, we showed the possible complete response with hormone-therapy associated to targeted therapy and highlighted the role of loco-regional treatment in this situation.